1469 results about "Nucleic acid molecule" patented technology

The invention belongs to the technical field of colloidal gold immunochromatography, and relates to a cetirizine monoclonal antibody, a nucleic acid molecule, a carrier, a detection kit and application thereof. The cetirizine monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, the sequence of the VH-CDR2 is as shown in SEQ ID NO.2, and the sequence of the VH-CDR3 is as shown in SEQ ID NO.3. The invention further discloses a preparation method of the cetirizine monoclonal antibody. The monoclonal antibody provided by the invention has high sensitivity to cetirizine, the lowest detection limit is 0.007 ng / mL, the quantitative range is 0.017-0.282 ng / mL, and the specificity is strong.

The invention discloses a tiny residual focus detection method and system based on ultra-high depth sequencing, and relates to the technical field of tiny residual focus intelligent detection.The tiny residual focus detection method comprises the following steps that on the basis of a sequencing library, splitting is conducted according to a sample index to obtain a to-be-detected sample, and a consensus sequence is obtained according to a molecular identifier of the to-be-detected sample; based on a consensus sequence, filtering out the consensus sequence of which the mass value is less than 25 or the family size is less than 3, and combining a variation type and a distance from a fragment edge as noise introduced into an original nucleic acid molecular chain; a context sequence (context) and a chain direction are used as noise for introducing the capture level of PCR amplification; on the basis of the noise level, the circulating tumor DNA level is estimated in combination with tumor priori knowledge, and the MRD state is determined by detecting the significance of molecular signal sources. According to the invention, the sensitivity and specificity of MRD detection are improved.

Provided herein are methods, compositions, and kits for detecting analytes of interest from biological samples using tagmentation. The method comprises: (a) hybridising a nucleic acid analyte to a capture probe on an array, wherein the capture probe comprises: (i) a spatial barcode and (ii) a capture domain; (b) extending the capture probe using the nucleic acid analyte as a template, thereby generating a barcoded nucleic acid molecule on the array, wherein the barcoded nucleic acid molecule comprises a complement of the sequence of the nucleic acid analyte; and (c) tagmenting the barcoded nucleic acid molecule or a derivative thereof using a transposome comprising a transposase to insert a transposon end sequence into the barcoded nucleic acid molecule or the derivative thereof, thereby generating a barcoded nucleic acid fragment, wherein the barcoded nucleic acid fragment comprises: (i) the barcode, (ii) the transposon end sequence, and (iii) at least a portion of a sequence of the nucleic acid analyte or a complement thereof.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

Relates to the technical field of medicines, provides keratin CF5, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF5, a nucleic acid molecule for coding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF5. The invention relates to a keratin CF5-containing pharmaceutical composition and application of the keratin CF5, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF5, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Provided are systems and methods for cell-free nucleic acid sequencing to assess a condition.Generally, cell-free nucleic acid samples are used to perform methyl sequencing, targeting specific regions associated with abnormal methylation.The methylation of cell-free nucleic acid molecules can be evaluated based on sequencing results.Various features can be derived from methylation evaluation and used in computational models to assess cell-free nucleic acid samples for a condition.

Belongs to the technical field of medicine, and provides keratin CF7, a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention provides keratin CF7, a nucleic acid molecule encoding the keratin CF7, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF7, a pharmaceutical composition containing the keratin CF7, and a preparation method of the keratin CF7. The invention also discloses application of the keratin CF7, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

The invention provides keratin CF3 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF3, a nucleic acid molecule encoding the keratin CF3, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF3, a pharmaceutical composition containing the keratin CF3, and a preparation method of the keratin CF3. The invention also discloses application of the keratin CF3, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

Provided herein is a recombinant protein comprising a transmembrane domain derived from a transmembrane domain of a wild type erythropoietin receptor (EPOR). Nucleic acid molecules encoding such recombinant proteins, recombinant constructs, vectors and cells containing the nucleic acid molecules, methods of producing such cells and therapeutic uses thereof are also provided.

The present document describes methods and systems for amplifying and quantifying amplification of a nucleic acid molecule, with a polymerase chain reaction (PCR) or a loop-mediated isothermal amplification (LAMP), by irradiating, with a heating activation light beam from a continuous wave laser a biological enzymatic reaction mixture in solution comprising a nucleic acid template, a polymerase enzyme, and chemically modified nanoparticles. Quantification of the amplification is achieved by irradiating the biological enzymatic reaction mixture during an annealing and / or elongation steps with an ultraviolet (UV) light source and measuring with a photodetector a transmission change in UV light transmission.

The invention provides keratin CF4 as well as a preparation method, a pharmaceutical composition and application thereof, and belongs to the technical field of medicines. Specifically, the invention provides keratin CF4, a nucleic acid molecule encoding the keratin CF4, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF4, a pharmaceutical composition containing the keratin CF4, and a preparation method of the keratin CF4. The invention also discloses application of the keratin CF4, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic drugs, antitussive and expectorant drugs, anticonvulsion drugs, antiepileptic drugs, antihypertensive drugs, anti-inflammatory drugs and antiviral drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

The invention relates to a beta-CTx binding antibody or an antigen binding fragment thereof, the beta-CTx binding antibody comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region contain HCDR and LCDR sequences; the invention also relates to corresponding isolated nucleic acid molecules, expression vectors and host cells. In addition, the invention also relates to a kit and a method for diagnosing osteoporosis in a subject.

Provided are systems and methods for analyte detection and analysis. A system can comprise an open substrate. The open substrate may be configured to rotate or otherwise move. The open substrate can comprise an array of individually addressable locations, with analytes immobilized thereto. The substrate may be spatially indexed to identify nucleic acid molecules from one or more sources, and / or sequences thereof, with the respective one or more sources. A solution comprising a plurality of probes may be directed across the array to couple at least one of the plurality of probes with at least one of the analytes to form a bound probe. A detector can be configured to detect a signal from the bound probe via scanning of the substrate while minimizing temperature fluctuations of the substrate or optical aberrations caused by bubbles.

The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. The nucleic acid molecule may be a nucleic acid molecule associated with CRISPR, (e.g., a guide RNA). A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule such as a guide RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DQ beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 114 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 143 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

Belongs to the technical field of medicines, and relates to keratin CF1, a preparation method, a pharmaceutical composition and application thereof, in particular to keratin CF1, a nucleic acid molecule for encoding keratin CFI, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF1. The invention relates to a keratin CF1-containing pharmaceutical composition and application of the keratin CF1, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF1, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

Belongs to the technical field of medicines, discloses keratin CF2, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF2, a nucleic acid molecule for encoding the keratin CF2, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF2. The invention relates to a keratin CF2-containing pharmaceutical composition and application of the keratin CF2, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF2, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

Belongs to the technical field of medicine, and provides keratin CF8, a preparation method, a pharmaceutical composition and application thereof. Provided are a keratin CF8, a nucleic acid molecule encoding the keratin CF8, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, a preparation method of the keratin CF8, and a pharmaceutical composition containing the keratin CF8. The invention also discloses application of the keratin CF8, the nucleic acid molecule, the expression vector, the host cell or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating, anti-convulsion, anti-epilepsy, antihypertensive, anti-inflammatory and antiviral drugs.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.

The invention discloses application of a tripterygium wilfordii exosome in preparation of an anti-cervical cancer medicine and a tumor angiogenesis inhibiting medicine, and relates to the field of biological medicine. The medicinal plant exosome derived from tripterygium wilfordii is successfully separated, and it is proved that the medicinal plant exosome can regulate related pathways through delivery of functional nucleic acid molecules to inhibit proliferation and migration of cervical cancer cells and promote active oxygen related apoptosis so as to be used for tumor treatment. The tripterygium wilfordii exosome can further act on vascular endothelial cells in a tumor microenvironment, the migration function of Hela cells is inhibited, and then the effect of resisting cell proliferation in the tumor microenvironment is achieved. The tripterygium wilfordii exosome has the advantages of being simple in preparation method, remarkable in tumor growth resistance and tumor cell migration inhibition effect, good in biocompatibility, high in delivery efficiency and the like, and can be used as a novel nano-drug for tumor treatment.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

A nucleic acid molecule sequencing method of the present disclosure, comprising: first acquiring a sequencing image of a target nucleic acid sample; performing image processing on the sequencing image by means of an image processing model, so as to obtain a target image, the image processing model being a model obtained by training constructed nucleic acid molecule true value images and corresponding simulation nucleic acid images; and performing nucleic acid molecule sequencing on the basis of the target image, so as to obtain a sequencing result corresponding to the target nucleic acid sample.

The present disclosure relates in some aspects to methods and compositions for generating a library of nucleic acids for analysis. In some aspects, a plurality of RNAs are processed and analyzed in situ in a sample or used to generate a plurality of barcoded nucleic acid molecules for analysis. Also provided are oligonucleotides, a plurality of free nucleotides, detection reagents, compositions, and systems for use in accordance with the methods.

The invention discloses a lipid compound for delivering a therapeutic agent as well as a preparation method and application of the lipid compound, and particularly discloses a compound shown in a formula I or pharmaceutically acceptable salt, stereoisomer, tautomer, solvate, chelate, non-covalent complex or precursor of the compound, the ionizable lipid compound can effectively deliver nucleic acid molecules, small molecule compounds and other drugs, and through comparison, the lipid nanoparticles are good in particle size distribution and high in encapsulation efficiency, the delivery effect can be obviously better than that of contrast lipid nanoparticles, and the requirement of in-vivo delivery can be met. (I)

Bispecific antibodies comprising mutations that decrease homodimerization and at least one immunogenic peptide inserted into a CHI or CL domain are provided. Proteins comprising an Fc variant of a parent Fc polypeptide wherein at least one immunogenic peptide is inserted into the parent Fc polypeptide and the insertion replaces amino acids of the parent Fc polypeptide are provided. Protein dimers and antibodies comprising the proteins of the invention are also provided as are nucleic acid molecules encoding same, pharmaceutical compositions comprising same and methods of treating cancer by administrating same. Methods of producing antibodies are also provided.

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.